Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial

About this Attention Score

• In the top 25% of all research outputs scored by Altmetric
• High Attention Score compared to outputs of the same age (92nd percentile)
• Good Attention Score compared to outputs of the same age and source (79th percentile)